Biovest
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Biovest International, Inc (OTCQB: BVTI) was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma. Biovest filed to reorganize under chapter 11 bankruptcy in 2008 and 2013, BiovaxID was refused European marketing authorization in 2015, and Biovest's stock listing was revoked in 2017.
Biovest International, Inc (OTCQB: BVTI) was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma.
Biovest filed to reorganize under chapter 11 bankruptcy in 2008 and 2013, BiovaxID was refused European marketing authorization in 2015, and Biovest's stock listing was revoked in 2017. BiovaxID obtained Orphan drug status with the FDA and has obtained positive Phase III clinical trial results.
After a median follow-up of 4.71 years (56.6 months, range: 12.6 - 89.3 months), the median disease-free survival in the BiovaxID arm was 44.2 months compared with 30.6 months in the control arm, which is a clinically and statistically significant difference (adj. p=0.029). Among the 75 patients receiving BiovaxID in the study, 35 received BiovaxID manufactured with an IgM isotype and 40 received BiovaxID manufactured with an IgG isotype with each treatment vaccine produced to correspond with the patient's tumor immunoglobulin isotype.
Of 40 patients receiving control, 25 had tumors with IgM isotype and 15 had tumors with IgG isotype. Two of the patients in the vaccinated treatment/control population had a tumor with mixed IgM/IgG isotypes and were excluded from this analysis.
Among 35 patients with IgM tumor isotype receiving BiovaxID manufactured with an IgM isotype, median time to relapse after randomization was 52.9 months versus 28.7 months in the IgM tumor isotype control-treated patients (log-rank p=0.001; HR=0.34 (p=0.002); [95% CI: 0.17-0.68]. Among 40 patients with IgG tumor isotype receiving BiovaxiD manufactured with an IgG isotype, median time to relapse after randomization was 35.1 months, versus 32.4 months in control-treated patients with IgG tumor isotype (log-rank p=0.807; HR=1.1 (p=0.807): [95% CI: 0.50-2.44].
In its multi-center, randomized, controlled Phase 3 clinical study, BiovaxID demonstrated that it can induce powerful anti-tumor immune responses while providing a median disease-free survival benefit of over 15 months, and a reduction of 42% in the risk of relapse, and in the company's Phase 2 clinical trial, 28% of patients who received BiovaxID remain in continuous remission at a median of 12.7 years of follow-up. The approval of Dendreon's Provenge on April 29, 2010, indicates the FDA's willingness to accept a new class of drugs called cancer vaccines, of which BiovaxID is one.
BiovaxID has also completed phase II trials for Mantle Cell Lymphoma and is being investigated for the treatment of other Non-Hodgkin's Lymphomas as well. On November 2, 2011, BiovaxID was granted seven years of U.S. market exclusivity for Waldenstrom's Macroglobulinemia, a third and rare type of Non-Hodgkin's Lymphoma.
Patents
Biovest has been granted many patents, including the following: Perfusion Bioreactors, Cell Culture Systems, and Methods for Production of Cells and Cell-Derived Products, Method and System for the Production of Cells and Cell Products and Applications Thereof, and Extra-Capillary Fluid Cycling System and Method for a Cell Culture Device.
See also
Dendreon Cancer vaccine Avax Technologies
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359475092 under CC BY-SA 4.0; modifications have been made.